Physician profile
Michael Scott Hewitt
NPI 1164489597
$2,246.66
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,806 · 2020: $106 · 2021: $132 · 2022: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gemini Mountain Medical, LLC | $1,679.16 | 2019-2021 | |
| Smith+Nephew, INC. | $172.91 | 2020-2022 | |
| Stryker Corporation | $147.11 | 2019-2022 | |
| Depuy Synthes Sales INC. | $93.76 | 2020 | |
| Janssen Pharmaceuticals, INC | $82.15 | 2019 | |
| Integra Lifesciences Corporation | $26.28 | 2022 | |
| Bardy Diagnostics, INC. | $15.87 | 2021 | |
| Pacira Therapeutics, INC. | $15.01 | 2019 | |
| Horizon Therapeutics Plc | $14.41 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$250,250.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.